Peptide Compounding Under USP 795 & 797: Quality Boundaries Explained

Why Compounding Scrutiny Is Reshaping Research Procurement

For most of the last decade, the term “compounding” carried a narrow meaning in the peptide context: pharmacy-prepared injectable formulations for patients, primarily 503A patient-specific preparations and, at larger scale, 503B outsourcing facility operations. The quality governance framework for this activity — USP <797> for sterile preparations, USP <795> for nonsterile — was largely a pharmacy operations issue.

That framing shifted when peptide compounding volumes scaled dramatically alongside GLP-1 receptor agonist demand, telehealth-driven peptide prescribing, and the consumer wellness market. ה FDA Pharmacy Compounding Advisory Committee meeting materials (July 2026) make clear that FDA views the compounded peptide market as requiring substantially more oversight than it has historically received. Enforcement actions, import alerts on bulk drug substance sourcing, and the formal exclusion of several peptide sequences from the 503A/503B compounding pathways have all followed.

The downstream effect for research procurement is meaningful. When regulators scrutinize how compounders document identity, טוֹהַר, sterility, and provenance of their starting materials, they are implicitly setting a quality floor that now defines what “adequate” peptide documentation looks like — not just for compounders, but for any supplier whose materials are reviewed in the same audit context.

The question for R&D decision-makers is not “does USP <797> apply to my custom synthesis order?” The question is: “could my supplier’s documentation withstand the level of scrutiny that compounding-quality reviewers are now applying?”

Defining the Categories: Where the Regulatory Lines Actually Fall

Before discussing what the scrutiny demands, it is worth establishing what each category of peptide supply actually is — because conflation of these categories is a primary source of procurement risk.

503A Compounding

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist or physician may compound a drug product from bulk drug substances for an identified patient with a valid prescription. The finished preparation is not FDA-approved. Per FDA’s compounding FAQ, 503A preparations are primarily overseen by state pharmacy boards and are exempt from premarket approval, cGMP, and certain labeling requirements — provided all statutory conditions are met. For injectable peptides, this means the preparation must be a sterile compounded sterile preparation (CSP) governed by USP <797>.

The bulk drug substance used in 503A compounding must come from an FDA-registered facility and be accompanied by a Certificate of Analysis. A label reading “research use only” or “for laboratory use only” is explicitly disqualifying — USP’s commentary on General Chapter <797> states that such language must not appear on substances used to compound CSPs.

503B Outsourcing Facilities

503B outsourcing facilities compound at larger scale for office stock or healthcare-facility use without patient-specific prescriptions. Under 503B, FDA oversight is substantially greater: facilities must register with FDA, comply with cGMP, and are subject to FDA inspections. The finished product is still not FDA-approved, but the manufacturing discipline expected approaches that of conventional drug manufacturing.

Research-Use-Only (RUO) Custom Synthesis

Research-use-only peptides occupy a legally distinct category. They are manufactured for laboratory research, not for human administration, and are not intended to enter the compounding pathway. Regulatory guidance is consistent that high HPLC purity and a CoA do not convert an RUO material into a permissible compounding API. The intended use and the supplier’s FDA registration status — not the analytical data alone — determine whether a material is appropriate for a compounding application.

Custom Synthesis for Biopharma R&ד

Custom synthesis for biopharma R&D sits in an analytically demanding middle ground. The material is not intended for human administration (at the preclinical stage), but it may be used in animal studies, in vitro assays, or IND-enabling studies that have direct regulatory implications. The quality documentation requirements for these materials are determined by the intended use and the quality system of the receiving institution — not by a single universal standard. But the analytical bar is rising.

Regulated Drug Manufacturing

Full cGMP drug manufacturing covers FDA-approved or regulated finished drug products. כָּאן, the impurity profiling, validated analytical methods, full batch records, and release specifications are non-negotiable and subject to regulatory review. This is the reference ceiling against which other quality tiers are increasingly compared.

What USP <797>’s 2023 Revision Actually Changed

The November 2023 revision of USP General Chapter <797> replaced the prior low-/medium-/high-risk framework with a two-category system — Category 1 and Category 2 — based primarily on whether enhanced microbial testing is performed and what beyond-use dating (BUD) is assigned.

קָטֵגוֹרִיָה 1 CSPs allow a BUD of 12 hours at controlled room temperature or 24 hours at refrigerated temperature, without requiring enhanced environmental monitoring or sterility testing.

קָטֵגוֹרִיָה 2 CSPs allow longer BUDs (up to 45 days at refrigerated temperature under certain conditions) but require substantially more: sterility and endotoxin testing, enhanced environmental monitoring with surface sampling monthly in conjunction with media fill testing, and more frequent viable air sampling for Category 2 CSPs than for Category 1.

The practical quality implications extend beyond pharmacy operations:

• Environmental monitoring is now more granular and more frequent, particularly for preparations with extended BUDs. Air sampling frequency, surface contamination testing intervals, and temperature/humidity recording requirements are all specified.

• Personnel qualification now includes role-based training, garbing competency, gloved fingertip testing, and media-fill competency assessments at defined intervals.

• Documentation depth has increased: cleaning and disinfection records, environmental control logs, validation records, and release-testing documentation are all required and auditable.

• Beyond-use dating is tied to demonstrated controls, not just preparation category. A supplier claiming extended stability without the environmental monitoring and testing record to support it is making an unverifiable claim.

These requirements define what a demonstrably controlled sterile manufacturing environment looks like. They do not formally apply to RUO custom synthesis. But they do establish a documentation vocabulary that rigorous buyers now apply to vendor audits across the board.

Traceability: The Chain-of-Custody Standard That Compounding Scrutiny Revealed

Traceability in the compounding context means something specific: the ability to trace a preparation backward through its bulk API lot, the testing that was performed on that lot, the personnel involved in compounding, the environmental conditions at the time of compounding, and forward through storage and dispensing. This is what a regulatorily defensible batch record looks like.

For research-grade custom synthesis, the traceability standard has historically been lower: a lot number on the vial, a CoA with HPLC and MS data, and a shipping record. That is no longer sufficient for materials destined for in vivo studies, IND-enabling work, or institutional procurement with formal quality agreements.

What a defensible traceability package now includes:

• Unique batch/lot identifier that matches the CoA, the physical vial label, and the raw analytical data from which the CoA was generated

• Raw-material chain of custody: which amino acid, resin, and reagent lots were used, with their own supplier-issued CoAs

• סינתזת פפטידים Synthesis and purification records: SPPS coupling conditions, deprotection sequences, cleavage conditions, purification method (RP-HPLC with column and mobile phase documented), and step yield at each stage

• Release testing linkage: the CoA must be derived from lot-specific testing, not template-populated from a prior batch or a reference standard run on a different lot

• Storage and shipping conditions: טֶמפֶּרָטוּרָה פפטידים סינתטיים excursion records if cold-chain is required

MOL Changes maintains a complete product quality traceability system in which each batch carries a unique identification code that records personnel, process steps, and environmental conditions from upstream synthesis through lyophilization and shipment — the model for what peptide supplier governance for raw materials and sterilization should look like.

The most common traceability failure in the research peptide market is not fabrication — it is template reuse. A CoA that shows the same chromatogram peak shape across multiple lot numbers, or a batch document where the “lot ID” is the only field changed, is not a traceability record. It is a data integrity failure.

⚠️ Warning: A CoA generated from a reference standard or prior batch run — rather than the actual lot being shipped — is a traceability failure regardless of how accurate the purity number appears. Request the raw HPLC integration table and MS spectrum to verify lot-specific data generation.

Impurity Profiling: The Dimension Where Research-Grade and GMP-Grade Diverge Most Sharply

The impurity profile of a synthetic peptide is not simply what is left after the main peak. It is a structured record of every peptide-related species above a defined reporting threshold, with structural identification for species above the identification threshold, and a qualification assessment for species above the qualification threshold.

For pharmaceutical manufacturing, the regulatory framework is now explicit. The EMA synthetic peptide guideline (effective June 2026) sets:

• Reporting threshold: >0.1% relative to drug substance

• Identification threshold: >0.5%

• Qualification threshold: >1.0%

Each impurity above these thresholds requires structural characterization — typically by orthogonal analytical methods covering size, charge, and hydrophobicity — not HPLC alone. א 2026 GMP peptide manufacturing compliance analysis notes that HPLC alone is insufficient for a complete impurity profile and that UHPLC-HRMS/MS is expected for peak identity confirmation at this level.

For a first GMP lot, typical acceptance criteria require HPLC purity >97% with no single impurity exceeding 1% — per established peptide quality control references, such as Polypeptide’s quality control specifications. This is not the same as a general-research standard of ≥95% HPLC purity, where impurities are summarized as “everything other than the main peak” without individual characterization.

The practical implications for research procurement:

The gap between these two documentation tiers is what makes “research-grade” a meaningful specification rather than a marketing label. Buyers who receive a CoA showing 95.2% HPLC purity with no further detail are receiving a material that may be entirely appropriate for in vitro binding assays or computational validation work — and entirely inappropriate for rodent pharmacokinetics, stability studies, or IND-enabling toxicology. The CoA does not make that distinction explicit; the buyer must.

The batch-specific CoA component architecture — traceability header, raw RP-HPLC data, HR-MS spectra, and counterion reporting — that research institutions are increasingly adopting mirrors what GMP-adjacent programs demand. The practical distinction is between documentation that describes a material and documentation that a receiving quality system can independently verify.

Certificates of Analysis: What a Defensible Document Actually Contains

A Certificate of Analysis is not a supplier’s affidavit that material is good. It is a primary analytical record linking a specific lot of material to specific test results generated by a defined method at a specific laboratory. When the CoA is constructed correctly, every claim it contains is reproducible and auditable.

The minimum elements for a defensible research-grade CoA are:

1. Peptide identification: full sequence, molecular formula, molecular weight (confirmed by MS, not calculated from sequence alone), and CAS number where applicable

2. Batch/lot traceability: unique alphanumeric lot identifier matching the vial label

3. Synthesis date and stated shelf life under the specified storage conditions

4. HPLC purity: expressed as percentage by peak area, with the analytical method specified — column, mobile phase, wavelength (typically 214 nm for peptide backbone), and gradient conditions

5. MS identity confirmation: measured molecular weight from ESI-MS or MALDI-TOF, not simply the calculated value

6. Testing laboratory identity and credentials: who performed the analysis and when

For materials intended for in vivo injectable use, add: 7. Endotoxin testing: method (typically LAL per USP <85>), result, and acceptance criterion 8. Sterility testing: method (per USP <71>) and result 9. Residual TFA quantification: with counterion exchange data if acetate or HCl salt form is required 10. Residual solvents: reported per ICH Q3C

A broader audit framework for evaluating third-party documentation quality — including how to assess whether a CoA represents lot-specific versus template-populated data — is available in the beyond-the-CoA peptide testing audit guide.

Key Takeaway: HPLC purity percentage is a single-point summary. The CoA elements that verify it — the raw chromatogram with integration table, the column and method documentation, the lot ID match — are what distinguish an analytical record from a formatted assertion.

The structural characteristics of a fraudulent or template-reused CoA are recognizable: identical peak shapes across lot numbers, purity values that cluster suspiciously (e.g., always 98.3%), absence of a method note, and a testing laboratory that is either unnamed or cannot be independently verified. These are not hypothetical edge cases — they represent documented patterns in the research peptide market.

What Public CoAs Reveal: A Documentation-Completeness Snapshot

The following observations are drawn from MOL Changes’ review of publicly posted and client-submitted peptide Certificates of Analysis across research-grade suppliers, anonymized and aggregated. They are intended to illustrate recurring documentation gaps, not to characterize any individual supplier.

Across the CoAs reviewed, three gaps recurred most often:

• Missing raw chromatogram data. A majority of research-grade CoAs stated a purity percentage without attaching the underlying RP-HPLC chromatogram and integration table. Without the raw trace, the stated percentage cannot be independently verified.

• Template-populated identity fields. A recurring pattern was a CoA in which molecular weight appeared as a calculated value rather than a measured one, with no accompanying MS spectrum. This does not prove a defect, but it removes the primary evidence that the shipped lot matches the stated sequence.

• Absent method documentation. Column type, mobile phase, gradient, and detection wavelength were frequently unspecified, making the purity figure non-reproducible by a receiving laboratory.

How to use this snapshot. These observations describe the distribution of documentation completeness, not the frequency of fraud. Most gaps reflect process maturity rather than intent. The practical takeaway is that completeness varies considerably across the research-grade market, and a buyer who does not specify required CoA elements in advance will receive whatever the supplier’s default template contains.

Note: The observations above are aggregated and anonymized. Specific figures and named examples will be added from MOL Changes’ internal audit records on request; readers should treat this section as indicative of documentation patterns rather than a statistically representative market survey.

Fit-for-Purpose Claims: The Most Overused and Least Defined Label in Peptide Procurement

“Fit for purpose” is not a quality specification. It is a procurement conclusion. The phrase is used, correctly, to mean that a material’s documented quality attributes are appropriate for the intended application — and is used, incorrectly, as a marketing shortcut for “good enough” without specifying what “good enough” means for what application.

The regulatory scrutiny on compounding has sharpened what fit-for-purpose means in practice by forcing an explicit mapping of quality attributes to intended use. The same mapping discipline belongs in research procurement.

A practical framework:

Thresholds reflect commonly applied industry practice and published regulatory guidance; acceptance criteria should be confirmed with the appropriate regulatory authority for the specific study design.

The fit-for-purpose decision is a responsibility that belongs to the buyer, not the supplier. A custom synthesis provider can document what a material is. Only the receiving team can determine whether those attributes are sufficient for the study type in which the material will be used. Accepting a “research grade” label without mapping it to specific analytical attributes — and then expecting the material to perform in a rodent GLP study — is a procurement failure, not a supplier failure.

This framing applies directly to the compounding scrutiny context. When a compounding pharmacy sources a bulk peptide API and that API lacks a documented impurity profile, the compounder cannot perform a meaningful release assessment. When a research team sources a custom peptide and the CoA lacks endotoxin data, the team cannot make an informed decision about whether the material is appropriate for an animal study. The documentation gap is structurally the same even though the regulatory category is different.

The emerging field standard is that buyers request a tier-specific documentation confirmation before purchase order release, not after — a practice that requires the supplier to publish, or at least commit to, the documentation package associated with each use tier in advance.

The Supplier’s Obligation: What Scrutiny-Proof Documentation Looks Like

The compounding quality conversation has clarified what documentation capable of surviving regulatory review actually requires. For custom synthesis providers serving biopharma R&ד, the practical translation is a commitment to lot-specific analytical transparency rather than template-generated summary data.

The elements that define a documentation-ready custom synthesis supplier:

Analytical infrastructure

• RP-HPLC purity data with raw chromatogram output (not just a summary percentage)

• High-resolution mass spectrometry: ESI-HRMS or MALDI-TOF with mass accuracy <5 ppm where required

• Orthogonal characterization for materials above basic research grade: IEX, SEC-HPLC, or CE as appropriate to the peptide class

• Endotoxin testing capability per USP <85> (LAL method)

• Sterility testing capability per USP <71>

• Residual solvent analysis and counterion quantification

Manufacturing environment

• Demonstrated sterile manufacturing capability for injectable-grade materials — typically a classified ISO environment with documented environmental monitoring, not merely a stated commitment to clean conditions

• Separation of research-grade and sterile-grade processing streams to prevent cross-contamination

Quality management

• Lot-specific CoA generation linked to raw analytical data, not template population

• Batch record documentation connecting synthesis, טָהֳרָה, and testing steps to the released lot

• Formal deviation and non-conformance handling with documented outcomes

MOL Changes operates within a מַחלָקָה 100 cleanroom manufacturing environment with a complete product quality traceability system — recording personnel involvement, process parameters, excipient and reagent lots, and environmental conditions from synthesis through lyophilization and shipment. For biopharma buyers evaluating whether a custom synthesis partner can support the quality documentation that their internal quality system or regulatory program requires, the baseline question is whether this infrastructure is demonstrated or merely described.

What This Means for Procurement Practice

The practical response to compounding scrutiny, for biopharma R&D decision-makers, is a quality intake process that explicitly ties procurement criteria to application type before purchase order release.

Three immediate actions that align procurement with the current quality landscape:

1. Require a use-tier classification at PO submission. Before placing an order, define in writing whether the material is intended for in vitro assays, cell-based assays, rodent in vivo studies, IND-enabling work, or clinical use. This classification determines the minimum CoA requirements and sterility specifications that apply.

2. Request the raw analytical data, not just the CoA summary. Ask the supplier for the unredacted RP-HPLC chromatogram with the integration table, the HR-MS spectrum showing the charge state distribution and mass accuracy, and the endotoxin testing report if applicable. If a supplier cannot provide these, the CoA is not independently verifiable.

3. Audit the traceability path. Confirm that the lot ID on the vial matches the lot ID on the CoA, which matches the lot ID in the raw analytical data, which matches the batch record that documents the synthesis and purification conditions. A missing link in this chain is a documentation failure, regardless of what the purity number says.

Documented patterns in the consumer peptide market point to the same structural cause: buyers accepting CoA summaries at face value rather than verifying the analytical record from which the summary was generated. The failure mode is not a bad analytical result — it is the absence of the underlying record that would let a third party confirm one was ever produced. ייצור פפטידים

The compounding standard — specifically the requirement that CSP release documentation be auditable, lot-specific, and traceable to the analytical method used — is the right model for this verification practice, regardless of whether the material being procured is technically a compounded drug.

Working With a Custom Synthesis Partner Who Understands the Stakes

If your program is operating at the boundary where research-grade quality governance is no longer adequate — scaling toward IND-enabling studies, moving from in vitro to in vivo work, or working with peptide sequences that require complex modifications and clean impurity profiles — the synthesis partner conversation needs to start with documentation architecture, not just purity percentage.

MOL Changes provides custom and catalog peptide synthesis supported by Class 100 sterile cleanroom manufacturing, full HPLC and MS analytical verification, endotoxin and sterility testing capability, and a lot-specific traceability system covering synthesis through shipment. For biopharma R&D teams that need a technical feasibility assessment for a specific sequence — including discussion of the expected impurity profile, sterility requirements, and documentation package for the intended study type — that conversation is the appropriate starting point.

Disclosure: MOL Changes is a commercial peptide synthesis provider with a direct commercial interest in the quality standards discussed in this article. This article is prepared for educational purposes and separates regulatory requirements from industry best practices and supplier-specific standards where possible. All regulatory thresholds and quality specifications cited are drawn from publicly available guidance documents and peer-reviewed sources, as listed in the References section. Content is written by the MOL Changes Technical Team and reviewed by its Quality & Regulatory Affairs Group; it is not independently peer-reviewed by a third party.

For technical questions about documentation requirements for specific peptide sequences or study types, contact the MOL Changes synthesis team at molchanges.com.

References

US Pharmacopeia

• USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations (revised November 2023). United States Pharmacopeia.

• USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. United States Pharmacopeia.

• USP General Chapter <71> Sterility Tests. United States Pharmacopeia.

• USP General Chapter <85> Bacterial Endotoxins Test. United States Pharmacopeia.

• USP. Commentary on General Chapter <797> (2022). https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-nf-commentary/797-commentary-20221101.pdf

US Food and Drug Administration

• FDA. Pharmacy Compounding Advisory Committee Meeting Materials (July 2026). https://www.fda.gov/media/193773/download

• FDA. Compounding and FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

• FDA. Compounding Law and Related Guidance (Section 503A and 503B of the FD&C Act).

European Medicines Agency

• EMA. Guideline on the Development and Manufacture of Synthetic Peptides (effective June 2026).

ICH

• ICH Q3C(R8). Impurities: Guideline for Residual Solvents. International Council for Harmonisation.

Additional industry references cited in text

• Neolab Peptides. GMP Peptide Manufacturing 2026 Compliance Guide. https://neolabpeptides.com/blogs/news/gmp-peptide-manufacturing-2026-compliance-guide

• Polypeptide Group. Quality Control Specifications. https://www.polypeptide.com/services/quality-control/

• MOL שינויים. Peptide Supplier Governance: Raw Materials and Sterilization. https://molchanges.com/peptide-supplier-governance-raw-materials-sterilization.html

• MOL שינויים. Beyond the CoA: Third-Party Peptide Testing Audit Guide. https://molchanges.com/beyond-the-coa-third-party-peptide-testing-audit-guide.html

For technical questions about documentation requirements for specific peptide sequences or study types, contact the MOL Changes synthesis team at molchanges.com.